Gepotidacin is an oral triazaacenaphthylene bacterial type II topoisomerase inhibitor approved based on data from the phase 3 EAGLE-1 study.
The FDA approval of berotralstat oral pellets offers a new prophylaxis option for children aged 2 years and older with hereditary angioedema.
The phase 3 MINT study evaluated inebilizumab, a CD-19 directed cytolytic antibody, in 238 patients with gMG, including those who were anti-AChR-Ab+ and anti-MuSK-Ab+.
ACIP votes to change hep B vaccination for infants; positive results for retatrutide; Omisirge approved; counterfeit Ozempic seized by FDA; gene therapy ...
HealthDay News — Federal officials say the US Food and Drug Administration (FDA) is reviewing reports of possible deaths in adults and children following COVID-19 vaccination. Federal officials say ...
HealthDay News — Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems have been reported. The review covers Beyfortus (from Sanofi ...
Guideline states that prochlorperazine IV and greater occipital nerve blocks must be offered to eligible adults requiring parenteral therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback